NIRSEVIMAB

Read in conjunction with Disclaimer

Formulary: Restricted For use as per WA Immunisation Schedule and WA Health Communicable Disease Control Directorate guidance.	
Presentation	**Prefilled Syringe:** • 50 mg in 0.5 mL (purple plunger rod) • 100 mg in 1 mL (light blue plunger rod)
Drug Class	Monoclonal antibody immunisation
Indication	**Prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease** for infants who meet the criteria determined by the Western Australian Immunisation Schedule and WA Respiratory Syncytial Virus (RSV) Immunisation Programs. **NOTE: Parent/Guardian consent is to be obtained prior to administration of all vaccinations.**
Special Considerations	• Avoid use in infants less than 1.6 kg and/or less than 29 weeks corrected gestational age. If considering discharge, consult Infectious Diseases (ID) for further advise in these infants. • For children undergoing cardiac surgery with cardiopulmonary bypass, an additional dose of nirsevimab is recommended as soon as the child is stable after surgery to ensure adequate nirsevimab serum levels. Refer to the product information for dosing advice. • Contraindicated for infants with severe allergy to any ingredients of nirservimab injection. • Caution should be taken with intramuscular injections for children with thrombocytopenia, coagulation disorders or on anticoagulation therapy.
Interactions	• No interaction studies have been conducted. Interactions with other medications are unlikely. • Nirsevimab can be co-administered with other scheduled vaccines. Ensure a different injection site is used.
Incompatibility	The contents of the nirsevimab prefilled syringe should not be combined with any fluids or other vaccinations prior to administration.
Side Effects	**Uncommon:** rash, injection site reaction (pain, redness, swelling), fever.
Monitoring	Clinically observe the infant for 15 minutes post administration for adverse reaction or anaphylaxis. Saturation and cardiorespiratory monitoring is not required following administration.
Storage & Stability	**Refrigerate between 2 to 8°C, do not freeze. Protect from light.** • May be kept at room temperature (below 25°C) for up to 8 hours. If not used within 8 hours, the syringe must be discarded. Do not return to the refrigerator.

INTRAMUSCULAR INJECTION

Presentation	**Prefilled Syringe:** • 50 mg in 0.5 mL (purple plunger rod) • 100 mg in 1 mL (light blue plunger rod)
Dosage	<table><tr><th>Working Weight</th><th>Dose</th></tr><tr><td>Less than 5 kg</td><td>50 mg (in 0.5 mL)</td></tr><tr><td>5 kg and greater</td><td>100 mg (in 1 mL)</td></tr></table> ***Do not prescribe unless consent has been confirmed.*** Nirsevimab should be prescribed for all eligible infants in preparation for discharge from hospital. For healthy full term infants, this may mean administering at the same time as their first dose of Hepatitis B vaccination.
Preparation	• Visually inspect prefilled syringe for particulate matter and discolouration. Nirservimab should be a clear to opalescent, colourless to yellow solution. • Remove the syringe cap off the nirsevimab syringe and attach a Luer lock needle.
Administration	***Do not administer unless consent has been confirmed.*** Administer the entire contents of the prefilled syringe as an intramuscular injection as per the Medication Administration Guideline.

Related Policies, Procedures, and Guidelines

HDWA Policies and Information:

Western Australian Immunisation Schedule

Respiratory Syncytial Virus

Respiratory Syncytial Virus (RSV) immunisation

Immunisation education

Clinical Practice Guidelines:

Neonatology - Immunisations

Consumer Information:

PCH RSV Immunisation for Children Health Facts Sheet

Pharmaceutical and Medicines Management Guidelines:

WNHS Cold Chain Management for Medications and Vaccines

CAHS Medication Refrigerators and Freezers

References

AusDI. Beyfortus™ (Nirsevimab) Solution for Injection. In: AusDI By Medical Director [Internet]. Australia: AusDI by Medical Director; 2023 [cited 2024 Mar 20]. Available from: https://www.ausdi.com/

Document history

<table>
<tr><td>Keywords</td><td colspan="5">Nirsevimab, Beyfortus, immunisation, RSV, respiratory syncytial virus, monoclonal antibody</td></tr>
<tr><td>Document Owner:</td><td colspan="5">Chief Pharmacist</td></tr>
<tr><td>Author/ Reviewer</td><td colspan="5">KEMH & PCH Pharmacy/Neonatology Directorate</td></tr>
<tr><td>Version Info:</td><td colspan="5">V1.0 – Inaugural protocol
V1.1 – Updated indication to align with WA Immunisation Schedule (Oct 2024)
V1.2 – Decision aid flow charts added (April 2025)
V1.3 – Links updated (April 2026)
V1.4 – Consent warnings added to dosage and administration section (June 2026)</td></tr>
<tr><td>Date First Issued:</td><td>04/04/2024</td><td>Last Reviewed:</td><td>03/10/2024</td><td>Review Date:</td><td>03/10/2029</td></tr>
<tr><td>Endorsed by:</td><td colspan="3">Neonatal Directorate Management Group</td><td>Date:</td><td>29/10/2024</td></tr>
<tr><td>NSQHS Standards Applicable:</td><td colspan="2">☒ Std 1: Clinical Governance</td><td colspan="3">☒ Std 4: Medication Safety</td></tr>
<tr><td colspan="6">Printed or personally saved electronic copies of this document are considered uncontrolled.
Access the current version from WNHS HealthPoint.</td></tr>
</table>

This document can be made available in alternative formats on request for a person with a disability.

© North Metropolitan Health Service 2024